Skip to main content
main-content

Expert opinion

Neuer Inhalt Free Registration

Gain full access to the latest clinical content available from Springer Nature

24-10-2017 | Rheumatoid arthritis | Editorial | Article

Demise of the triple

Editorial Board member Marc Cohen reviews the use of triple therapy for the treatment of rheumatoid arthritis, and discusses the possible reasons for its underutilization compared with biologic therapies.

Author:
Marc D Cohen

16-08-2017 | Juvenile idiopathic arthritis | Editorial | Article

What’s in a name: The complexity of juvenile idiopathic arthritis

The complexity of juvenile idiopathic arthritis is discussed here by Editorial Board member Sangeeta Sule, focusing on how clinical decisions can be better informed in order to provide more precise and personalized treatment options.

Author:
Sangeeta Sule

18-07-2017 | Gout | Editorial | Article

The future of gout: Are you ready for it?

Editorial Board member Fernando Pérez-Ruiz discusses the recent increase in gout-related hospitalizations and asks if we are ready for a future of clinical inertia and passivity when it comes to the management of gout.

Author:
Fernando Pérez-Ruiz

08-06-2017 | NSAIDs | Editorial | Article

Cardiovascular risk of non-steroidal anti-inflammatory drugs

Editorial Board member Oliver FitzGerald reviews the cardiovascular risk of non-steroidal anti-inflammatory drugs such as celecoxib, naproxen, and ibuprofen in light of results from the PRECISION study.

Author:
Oliver FitzGerald

24-05-2017 | Gout | Editorial | Article

Taking gout seriously

Gout is prevalent in developed countries but does not receive the same investment as conditions such as rheumatoid arthritis. Editorial Board member Fernando Pérez-Ruiz suggests that rheumatologists and healthcare providers need to start taking gout seriously.

Author:
Fernando Pérez-Ruiz

Meet our Editorial Board

image credits